STOCK TITAN

Sensei Biotherapeutics Inc - SNSE STOCK NEWS

Welcome to our dedicated news page for Sensei Biotherapeutics (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sensei Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sensei Biotherapeutics's position in the market.

Rhea-AI Summary
Sensei Biotherapeutics to present initial safety and pharmacokinetic data from its Phase 1/2 trial of SNS-101 at the SITC 38th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences clinical trial
-
Rhea-AI Summary
Sensei Biotherapeutics presents trial-in-progress poster for SNS-101 at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
-
Rhea-AI Summary
Sensei Biotherapeutics announces progress in clinical trial for SNS-101
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.11%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary
Sensei Biotherapeutics to participate in investor conferences in September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) to participate in fireside chat at Canaccord Genuity’s 43rd Annual Growth Conference, offering webcast of presentation and replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
-
Rhea-AI Summary
Sensei Biotherapeutics, Inc. will host a virtual event featuring Dr. James Gulley, a renowned expert in cancer immunotherapy. The event will discuss the potential of Sensei's lead candidate, SNS-101, as a transformative treatment option for patients with solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
conferences
Sensei Biotherapeutics Inc

Nasdaq:SNSE

SNSE Rankings

SNSE Stock Data

26.32M
16.41M
34.65%
10.55%
0.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Rockville

About SNSE

sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit